Pharmacological MEK inhibition promotes polyclonal T-cell reconstitution and suppresses xenogeneic GVHD.
Cell Immunol
; 367: 104410, 2021 09.
Article
en En
| MEDLINE
| ID: mdl-34274730
ABSTRACT
Rapid immune reconstitution without developing graft-versus-host disease (GVHD) is required for the success of allogeneic hematopoietic stem cell transplantation. Here, we analyzed the effects of pharmacological MEK inhibition on human polyclonal T-cell reconstitution in a humanized mouse GVHD model utilizing deep sequencing-based T-cell receptor (TCR) repertoire analysis. GVHD mice exhibited a skewed TCR repertoire with a common clone within target organs. The MEK inhibitor trametinib ameliorated GVHD and enabled engraftment of diverse T-cell clones. Furthermore, trametinib also ameliorated GVHD sparing diverse T cell repertoire, even when it was given from day 15 through 28. Although tacrolimus also reduced development of GVHD, it disturbed diverse T cell reconstitution and resulted in skewed TCR repertoire. Thus, trametinib not only suppresses GVHD-inducing T cells but also promotes human T cell reconstitution in vivo, providing a novel rationale for translational studies targeting human GVHD.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Piridonas
/
Pirimidinonas
/
Linfocitos T
/
Trasplante de Células Madre Hematopoyéticas
/
Quinasas de Proteína Quinasa Activadas por Mitógenos
/
Inhibidores de Proteínas Quinasas
/
Enfermedad Injerto contra Huésped
/
Inmunosupresores
Límite:
Animals
/
Humans
Idioma:
En
Año:
2021
Tipo del documento:
Article